GO:0090398 cellular senescence: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090398 cellular senescence is a biological process in which normal cells undergo irreversible cell cycle arrest in response to cellular stress.
• Senescent cells remain metabolically active and secrete a complex mixture of factors known as the senescence-associated secretory phenotype (SASP), which influences tissue microenvironments.
• Key effector pathways include the p53/p21 and p16/RB tumor suppressor axes, which enforce and maintain the growth-arrested state.
• Cellular senescence is a hallmark of aging and contributes to both protective tumor suppression and detrimental age-related pathologies.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential for dissecting causal roles of senescence-associated genes.
• Research methods such as RNA-seq, proteomics, and imaging are widely used to characterize senescence and its secretory program.
Description
Cellular senescence (GO:0090398) is a biological process defined as a cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest. This process was first described in human fibroblasts and has since been recognized as a fundamental mechanism in development, tissue homeostasis, and aging. Senescent cells remain viable and metabolically active but are permanently withdrawn from the cell cycle, often accompanied by profound changes in gene expression, chromatin organization, and secretory activity. The importance of cellular senescence for researchers spans cancer biology, immunology, neuroscience, and regenerative medicine, as it acts as a double-edged sword: it suppresses tumorigenesis early in life but can promote chronic inflammation and tissue dysfunction when senescent cells accumulate with age. Understanding the molecular players and regulatory networks of GO:0090398 is therefore critical for developing senotherapeutics and for interpreting age-related disease mechanisms.
cellular senescence At A Glance
| GO ID | GO:0090398 |
|---|---|
| GO term | cellular senescence |
| Ontology | biological_process |
| Synonym | none |
| Major function | Irreversible cell cycle arrest in response to cellular stress, with associated secretory and metabolic changes |
| Key effector pathways | p53/p21 and p16/RB tumor suppressor pathways |
| Associated phenotype | Senescence-associated secretory phenotype (SASP) |
| Physiological roles | Tumor suppression, embryonic development, wound healing, immune surveillance |
| Pathological roles | Aging, cancer, fibrosis, neurodegeneration, skin aging |
What Is GO:0090398?
According to the Gene Ontology, GO:0090398 cellular senescence is a cell aging process stimulated in response to cellular stress, whereby normal cells lose the ability to divide through irreversible cell cycle arrest. In other words, it is a stress-induced state of permanent proliferative arrest that is distinct from quiescence and terminal differentiation, and it is accompanied by characteristic molecular and phenotypic changes.
Why Is cellular senescence Important in Cell Biology?
Cellular senescence is critically important because it functions as a primary barrier against cancer but also drives aging and multiple chronic diseases when senescent cells persist. The process is implicated in a wide range of conditions, including cancer, fibrosis, neurodegeneration, and skin aging, making it a prime target for therapeutic intervention. Researchers studying GO:0090398 aim to understand how senescent cells arise, how they are maintained, and how they can be selectively eliminated or modulated to improve healthspan.
• Tumor suppression: senescence prevents the proliferation of damaged or oncogene-activated cells.
• Aging hallmark: accumulation of senescent cells contributes to tissue and organismal aging.
• Chronic inflammation: the SASP promotes sterile inflammation and tissue remodeling.
• Cancer therapy: induction of senescence is a goal of many chemotherapeutic and radiotherapeutic strategies.
• Age-related diseases: senescence is linked to osteoarthritis, atherosclerosis, and neurodegeneration.
• Skin aging: senescent fibroblasts and keratinocytes contribute to wrinkles and impaired wound healing.
• Androgenetic alopecia: senescent dermal papilla cells are implicated in hair follicle miniaturization.
• Regenerative medicine: clearing senescent cells improves tissue regeneration in preclinical models.
• Biomarker development: senescence markers such as p16 and SASP factors are used to detect senescent cells in tissues.
• Therapeutic targeting: senolytics and senomorphics are being developed to eliminate or modulate senescent cells.
What Happens During cellular senescence?
Initiation by cellular stress
In simple terms: Cells encounter damaging stress that triggers the senescence program.
Cellular senescence is initiated by a variety of stressors, including telomere shortening, oxidative stress, DNA damage, oncogene activation, and chemotherapy. These stresses activate DNA damage response pathways and tumor suppressor networks, leading to the engagement of the senescence program. The type and intensity of the stress influence the specific senescence subtype and its molecular features.
Stable cell cycle arrest
In simple terms: The cell permanently stops dividing, even if the stress is removed.
A hallmark of senescence is irreversible cell cycle arrest, typically mediated by the p53/p21 and p16/RB pathways. p21 inhibits cyclin-dependent kinases, while p16 maintains RB in its active, growth-suppressive state. This arrest is distinct from quiescence because it cannot be reversed by mitogenic stimuli.
Senescence-associated secretory phenotype (SASP)
In simple terms: Senescent cells release a cocktail of signals that affect neighboring cells.
Senescent cells develop a complex secretory program known as the SASP, which includes pro-inflammatory cytokines, chemokines, growth factors, and matrix metalloproteinases. The SASP can reinforce senescence in neighboring cells, recruit immune cells, and remodel the extracellular matrix. It is a major mediator of the systemic effects of senescent cells in aging and disease.
Metabolic and chromatin remodeling
In simple terms: Senescent cells change their metabolism and DNA packaging.
Senescent cells undergo profound metabolic reprogramming, including increased glycolysis, altered lipid metabolism, and mitochondrial dysfunction. Chromatin remodeling, such as the formation of senescence-associated heterochromatin foci (SAHF), contributes to the stable repression of proliferation genes. These changes support the long-term survival of senescent cells despite the growth arrest.
Immune clearance and persistence
In simple terms: The immune system usually removes senescent cells, but they can accumulate with age.
In young organisms, senescent cells are efficiently cleared by immune cells such as natural killer cells and macrophages. However, with aging or chronic stress, immune surveillance declines, leading to the accumulation of senescent cells in tissues. This persistence contributes to age-related tissue dysfunction and chronic inflammation.
Key Genes Involved in GO:0090398 cellular senescence
The following genes and proteins are central to the regulation and execution of cellular senescence (GO:0090398).
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Tumor suppressor that induces p21 and triggers senescence in response to DNA damage | Most frequently mutated in cancers; key node for senescence induction |
| CDKN1A (p21) | Cyclin-dependent kinase inhibitor that enforces cell cycle arrest | Biomarker of senescence; mediates p53-dependent arrest |
| CDKN2A (p16) | Inhibits CDK4/6, activating RB and maintaining stable arrest | Classic senescence marker; tumor suppressor |
| RB1 | Retinoblastoma protein that blocks S-phase entry when active | Central effector of the p16/RB pathway |
| IL6 | Pro-inflammatory cytokine and SASP component | SASP marker; promotes paracrine senescence |
| IL8 | Chemokine involved in SASP and immune cell recruitment | SASP marker; linked to inflammation |
| CXCL1 | Chemokine that reinforces senescence and inflammation | SASP factor; potential therapeutic target |
| MMP3 | Matrix metalloproteinase that remodels extracellular matrix | SASP component; implicated in tissue remodeling |
| SERPINE1 (PAI-1) | Inhibitor of plasminogen activators; promotes senescence | SASP factor; marker of senescence |
| LMNB1 | Lamin B1; its loss is a hallmark of senescence | Senescence biomarker; chromatin changes |
| HMGB1 | Chromatin protein that translocates to extracellular space in senescence | SASP mediator; inflammation |
| ATM | DNA damage sensor kinase that activates p53 in response to stress | Upstream regulator of senescence initiation |
| ATR | DNA damage response kinase involved in replication stress-induced senescence | Regulator of senescence in response to replication stress |
| CHEK1 | Checkpoint kinase that stabilizes p53 and promotes arrest | Potential target to modulate senescence |
| CHEK2 | Checkpoint kinase that phosphorylates p53 and BRCA1 | Linked to DNA damage-induced senescence |
| E2F1 | Transcription factor that can induce both proliferation and senescence | Context-dependent regulator of senescence |
| MYC | Oncogene that can induce senescence when hyperactivated | Model for oncogene-induced senescence |
| RAS | Oncogene; activated RAS induces senescence in primary cells | Classic model for oncogene-induced senescence |
How Is cellular senescence Regulated?
Cellular senescence is regulated by a complex network of signaling pathways, including the p53/p21 and p16/RB tumor suppressor axes, which are activated by DNA damage and oncogenic stress. The DNA damage response kinases ATM and ATR phosphorylate p53, leading to p21 induction and cell cycle arrest. The SASP is regulated by transcription factors such as NF-kB and C/EBPbeta, as well as by epigenetic modifiers. Metabolic regulators, including mTOR and AMPK, also influence the senescence program and its secretory phenotype. Additionally, the integrated stress response (ISR) can modulate senescence in a context-dependent manner.
cellular senescence and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Cancer, premature aging | Knockout and point mutation in cancer cell lines and organoids |
| CDKN2A (p16) | Melanoma, aging, atherosclerosis | Knock-in reporter for senescence detection |
| IL6 | Chronic inflammation, cancer | Knockout in senescent fibroblasts to study SASP |
| LMNB1 | Hutchinson-Gilford progeria syndrome, aging | Overexpression and knockout to assess senescence markers |
| RAS | Oncogene-induced senescence, cancer | Point mutation (G12V) knock-in to induce senescence |
Cellular senescence in cancer
Cellular senescence acts as a potent tumor suppressor mechanism by preventing the proliferation of cells with oncogenic mutations or DNA damage. However, senescent cells that accumulate in tumors can promote cancer progression through the SASP, which stimulates angiogenesis, inflammation, and immune evasion. This dual role makes senescence a complex target in oncology, with therapeutic strategies aiming to either induce senescence in cancer cells or eliminate senescent cells from the tumor microenvironment.
Cellular senescence in aging and age-related diseases
The accumulation of senescent cells with age is a hallmark of aging and contributes to a variety of age-related pathologies, including cardiovascular disease, neurodegeneration, and metabolic disorders. Senescent cells drive chronic low-grade inflammation, known as inflammaging, through the SASP. Targeting senescent cells with senolytics has been shown to improve healthspan in preclinical models, highlighting the clinical potential of modulating GO:0090398.
Cellular senescence in skin aging and hair loss
In the skin, senescent fibroblasts and keratinocytes contribute to impaired wound healing, loss of elasticity, and wrinkle formation. Senescent dermal papilla cells have been implicated in androgenetic alopecia, suggesting that senescence modulation could be a therapeutic strategy for hair loss. Natural polyphenols and other compounds have been studied for their ability to target senescent cells in the skin.
From cellular senescence-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TP53 prevent senescence? | TP53 knockout cell lines (e.g., HCT116, RPE1) |
| Does a specific point mutation in CDKN2A affect p16 function? | CDKN2A point mutation knock-in via CRISPR |
| Can a reporter gene track senescence in real time? | Knock-in of fluorescent reporter at CDKN2A or LMNB1 locus |
| Does overexpression of a candidate gene induce senescence? | Doxycycline-inducible overexpression in primary fibroblasts |
| What is the role of a SASP factor in paracrine senescence? | Knockout of IL6 or IL8 in senescent cells followed by co-culture |
| Can a gene mutation alter sensitivity to senolytics? | CRISPR knockout of BCL-2 family genes in senescent cells |
How to Study the cellular senescence Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identification of senescence markers and SASP factors |
| Proteomics | Protein abundance and modifications | Characterization of senescence-associated proteome |
| SA-beta-gal staining | Senescence-associated beta-galactosidase activity | Detection of senescent cells in culture and tissue |
| Immunofluorescence | Protein localization and expression (e.g., p16, p21, LMNB1) | Validation of senescence in situ |
| CRISPR knockout screens | Gene essentiality and regulators of senescence | Discovery of novel senescence modulators |
| Senescence-associated heterochromatin foci (SAHF) imaging | Chromatin organization changes | Assessment of deep senescence |
| ELISA | Secreted protein levels (e.g., IL6, IL8) | Quantification of SASP |
| Flow cytometry | Cell cycle status and surface markers | Sorting and analysis of senescent cells |
Transcriptomic profiling (RNA-seq)
RNA sequencing is widely used to characterize the gene expression changes associated with cellular senescence, including the upregulation of CDKN1A, CDKN2A, and SASP factors. It allows researchers to identify novel senescence markers and to dissect the regulatory networks downstream of p53 and RB.
Proteomics and secretome analysis
Mass spectrometry-based proteomics can quantify global protein changes in senescent cells, while secretome analysis identifies SASP components released into the culture medium. These methods are essential for understanding the functional impact of senescence on the tissue microenvironment.
Imaging and senescence-associated beta-galactosidase (SA-beta-gal) staining
SA-beta-gal staining at pH 6.0 is a classic histochemical marker for senescent cells in culture and tissues. Immunofluorescence for p16, p21, and LMNB1, along with chromatin stains such as DAPI for SAHF, provides complementary spatial information.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout or activation screens can identify genes that regulate the induction or maintenance of senescence. These screens are powerful for discovering new therapeutic targets and for understanding the genetic dependencies of senescent cells.
How CRISPR Can Be Used to Study GO:0090398 cellular senescence
Knockout
CRISPR knockout is used to delete genes such as TP53, CDKN1A, or CDKN2A to test their requirement for senescence induction or maintenance. Knockout of SASP factors like IL6 or IL8 helps determine their role in paracrine senescence and inflammation.
Point Mutation
Point mutations can be introduced into genes like TP53 or RAS to model specific cancer-associated variants and study their impact on senescence. For example, knock-in of the RAS G12V mutation induces oncogene-induced senescence in primary cells.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) at endogenous loci such as CDKN2A or LMNB1 allows real-time tracking of senescence in live cells and tissues. This approach is valuable for isolating senescent cells for downstream analysis.
Overexpression
CRISPR activation (CRISPRa) or inducible overexpression systems can drive candidate genes to test whether they are sufficient to induce senescence. Overexpression of oncogenes like MYC or RAS is a classic method to trigger senescence in vitro.
How EDITGENE Supports cellular senescence Research
Researchers studying cellular senescence-related genes often need to determine whether a candidate gene is causally involved in the induction, maintenance, or reversal of the senescent state. This requires precise genetic manipulation, which can be achieved through CRISPR-based knockout, point mutation, knock-in, or overexpression models. EDITGENE provides end-to-end services to generate such models and to support functional genomics studies of GO:0090398.
Contact EDITGENE today to design your custom CRISPR model for cellular senescence research.
Frequently Asked Questions About cellular senescence
What is cellular senescence (GO:0090398)?
Cellular senescence is a biological process in which normal cells undergo irreversible cell cycle arrest in response to cellular stress, as defined by the Gene Ontology.
What genes are involved in cellular senescence?
Key genes include TP53, CDKN1A (p21), CDKN2A (p16), RB1, IL6, IL8, and LMNB1, among others.
What is the senescence-associated secretory phenotype (SASP)?
The SASP is a complex mixture of cytokines, chemokines, growth factors, and proteases secreted by senescent cells, which affects the tissue microenvironment.
How is cellular senescence detected in the laboratory?
Common methods include SA-beta-gal staining, immunofluorescence for p16 and p21, loss of LMNB1, and RNA-seq for SASP markers.
What is the difference between senescence and quiescence?
Senescence is an irreversible cell cycle arrest, whereas quiescence is a reversible non-dividing state that can be reverted by mitogenic signals.
Can cellular senescence be reversed?
Senescence is generally considered irreversible, but some studies suggest that certain senescent cells can be eliminated or modulated by senolytics or genetic manipulation.
What are senolytics?
Senolytics are drugs that selectively kill senescent cells, and they are being developed to treat age-related diseases.
How does cellular senescence contribute to aging?
Accumulation of senescent cells with age leads to chronic inflammation and tissue dysfunction, contributing to the aging phenotype.
What is oncogene-induced senescence?
Oncogene-induced senescence is a protective response triggered by hyperactive oncogenes such as RAS or MYC, which prevents uncontrolled proliferation.
How can CRISPR be used to study cellular senescence?
CRISPR can create knockout, point mutation, knock-in, or overexpression models to test the causal role of specific genes in senescence.
Conclusion
Cellular senescence (GO:0090398) is a fundamental biological process that plays dual roles in tumor suppression and aging. Understanding its molecular mechanisms and regulatory networks is essential for developing therapeutic strategies against cancer and age-related diseases. CRISPR-based models and advanced omics technologies are indispensable tools for dissecting the genetic basis of senescence, and EDITGENE provides comprehensive services to support this research.
References
- 1. Hernandez-Segura A et al.. 2018. Hallmarks of Cellular Senescence.. Trends Cell Biol 28(6):436-453 PMID: 29477613
- 2. Csekes E et al.. 2021. Skin Aging, Cellular Senescence and Natural Polyphenols.. Int J Mol Sci 22(23) PMID: 34884444
- 3. Regulski MJ. 2017. Cellular Senescence: What, Why, and How.. Wounds 29(6):168-174 PMID: 28682291
- 4. Roger L et al.. 2021. Mechanisms and Regulation of Cellular Senescence.. Int J Mol Sci 22(23) PMID: 34884978
- 5. Zeng Q et al.. 2024. Lipids and lipid metabolism in cellular senescence: Emerging targets for age-related diseases.. Ageing Res Rev 97:102294 PMID: 38583577
- 6. de Magalhães JP. 2024. Cellular senescence in normal physiology.. Science 384(6702):1300-1301 PMID: 38900869
- 7. Deng Y et al.. 2023. Cellular Senescence: Ageing and Androgenetic Alopecia.. Dermatology 239(4):533-541 PMID: 37088073
- 8. Salama R et al.. 2014. Cellular senescence and its effector programs.. Genes Dev 28(2):99-114 PMID: 24449267
